Atara Biotherapeutics, Inc. (NASDAQ:ATRA) Q3 2020 Earnings Conference Call November 9, 2020 4:30 PM ET Company Participants Eric Hyllengren - Vice President of Investor Relations & Finance Pascal Touchon - President & Chief Executive Officer Jakob Dupont - Executive Vice President & Global Head of Research & Development Utpal Koppikar - Chief Financial Officer Joe Newell - Chief Operations Officer AJ Joshi - Chief Medical Officer Kristin Yarema - Chief Commercial Officer Conference Call Participants John Ne ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-36548 ATARA BIOTHERAPEUTICS, INC. (Exact name of Registrant as specified in its Charter) Delaware 46-0920988 (State or other jurisdicti ...

Atara Biotherapeutics, Inc. (NASDAQ:ATRA) Q2 2020 Earnings Conference Call August 5, 2020 4:30 PM ET Company Participants Eric Hyllengren - Investor Relations Pascal Touchon - President and Chief Executive Officer Utpal Koppikar - Chief Financial Officer Joe Newell - Chief Operations Officer A.J. Joshi - Chief Medical Officer Jakob Dupont - EVP and Global Head of Research and Development Kristin Yarema - Chief Commercial Officer Conference Call Participants Salim Syed - Mizuho Securities Benjamin Burnett - ...

CONFIDENTIAL 1 ATARA BIO® Investor Presentation August 5, 2020 Ola EBV+ PTLD survivor Nasdaq: ATRA Forward-Looking Statements This presentation and the accompanying oral presentation contain forward-looking statements made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical facts contained in this presentation, including statements regarding our future results of operations and financial position, business strateg ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to | --- | --- | |-----------------------------------------------------------------------------------------------------------------------|-------------------------------- ...

Atara Biotherapeutics, Inc. (NASDAQ:ATRA) Q1 2020 Results Conference Call May 6, 2020 4:30 PM ET Company Participants Eric Hyllengren - Investor Relations Pascal Touchon - President and Chief Executive Officer Utpal Koppikar - Chief Financial Officer Joe Newell - Chief Operations Officer A.J. Joshi - Chief Medical Officer Conference Call Participants Marc Frahm - Cowen and Company John Newman - Canaccord Genuity Salim Syed - Mizuho Securities Yigal Nochomovitz - Citigroup Tony Butler - Roth Capital Andrea ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission file number 001-36548 ATARA BIOTHERAPEUTICS, INC. (Exact name of Registrant as specified in its Charter) Delaware 46-0920988 (State or other jurisdiction o ...

Financial Data and Key Metrics Changes - Atara Biotherapeutics ended 2019 with cash, cash equivalents, and short-term investments totaling $259.1 million, down from $282.9 million as of September 30, 2019 [21] - Proforma cash and investments as of December 31, 2019, including ATM and option exercise proceeds from January 2020, was $282.7 million [21] Business Line Data and Key Metrics Changes - The company is conducting a Phase 3 clinical trial with tab-cel for patients with EBV-associated PTLD, with 38 sites actively enrolling patients in the U.S. and Australia [8][9] - The overall response rate for the HCT cohort in the tab-cel study was 55%, with a two-year estimated overall survival of 79% [11] - For the SOT cohort, the overall response rate was 82%, and the two-year estimated overall survival was 81% [11] Market Data and Key Metrics Changes - The potential indication for tab-cel in relapsed refractory PTLD is considered an ultra-rare disease, with several hundred patients in the U.S. and a similar number in Europe [55] - The company anticipates that the multi-cohort study planned for the second half of 2020 could lead to up to six additional indications, increasing the treatable population by at least a factor of four [55] Company Strategy and Development Direction - Atara is focused on advancing its T-cell immunotherapy programs, particularly the tab-cel platform, and has extended its cash runway into Q2 2021 [8][21] - The company aims to leverage its manufacturing capabilities to create a competitive advantage in off-the-shelf, allogeneic T-cell immunotherapy [20][72] - Atara is also exploring partnerships to access its off-the-shelf T-cell platform and other product portfolios [20][73] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the progress made in 2019 and the positioning for success in 2020, particularly regarding key milestones for tab-cel [22] - The company is optimistic about the potential of its innovative therapies and the interest from potential partners [20][73] Other Important Information - Atara has appointed Kristin Yarema as the new Chief Commercial Officer, bringing extensive experience in hematology, oncology, and autoimmune disease commercialization [20] - The company is on track to initiate enrollment for a randomized, placebo-controlled Phase 1b study of ATA188 in the second or third quarter of 2020 [16] Q&A Session Summary Question: Update on tab-cel enrollment and interim analysis - Management confirmed that they are not commenting on enrollment at this stage but reiterated plans to initiate BLA filing in the second half of 2020 following a pre-BLA meeting with the FDA [25][26] Question: Target number of trial sites for tab-cel - Currently, there are 38 sites open in the U.S., and the company anticipates enrolling up to 24 sites in Europe [33] Question: Data release timeline for ATA188 - Six-month data for all cohorts is expected in the first half of 2020, with 12-month data for the first three cohorts anticipated in the second half of 2020 [35] Question: Timing for results from the nasopharyngeal carcinoma study - The final patient has been enrolled, and results will be evaluated as the landscape matures [40] Question: Market size for EBV+ relapsed refractory PTLD - The company estimates several hundred patients in the U.S. and Europe could benefit from tab-cel, with plans for additional indications to increase the treatable population [55]